FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138616221> ?p ?o ?g. }

• W3138616221 endingPage "644" @default.
• W3138616221 startingPage "638" @default.
• W3138616221 abstract "Prurigo lesions in atopic dermatitis are intractable. This single-center, retrospective study examined dupilumab’s clinical effects on intractable prurigo. Twenty adult atopic dermatitis patients (12 with prurigo, eight without) were administrated dupilumab. Its effects on itching and disease severity were examined with Numerical Rating Scale–Itch (NRS-I), Eczema Area and Severity Index (EASI), and Investigator Global Assessment (IGA) scores; body surface areas (BSA); and thymus- and activation-regulated chemokine (TARC), total immunoglobulin (Ig)E, and eosinophil levels. NRS-I scores, EASI scores, TARC levels, and total IgE levels before dupilumab treatment were not statistically different between the prurigo and non-prurigo groups. With dupilumab treatment, NRS-I scores, EASI scores, IGA scores, BSA, TARC levels, and total IgE levels were significantly reduced from baseline in both groups at 1–2 months and onward, but skin symptom improvement in the prurigo group was slower than in the non-prurigo group, as evidenced by significantly higher EASI scores, BSA, and TARC levels at several time points during the 12 months of dupilumab treatment. Prurigo patients were slower in EASI-50 achievement and significantly lower in EASI-90 achievement at 12 months than non-prurigo patients. Adherence to dupilumab was not different, but total equivalent amounts of concomitant therapeutic agents (corticosteroids and tacrolimus) used during dupilumab treatment were significantly higher in the prurigo group (median, 56.2 g/week) than in the non-prurigo group (median, 33.7 g/week). There were 2.2 adverse events per patient on average; ocular complaints were most frequent. Dupilumab was effective in treating intractable prurigo, but despite significantly greater concomitant therapeutic agent use, skin symptom improvement was slower in prurigo patients than in non-prurigo patients." @default.
• W3138616221 created "2021-03-29" @default.
• W3138616221 creator A5002431268 @default.
• W3138616221 creator A5009716651 @default.
• W3138616221 creator A5010904358 @default.
• W3138616221 creator A5043225877 @default.
• W3138616221 creator A5068749718 @default.
• W3138616221 date "2021-03-20" @default.
• W3138616221 modified "2023-10-16" @default.
• W3138616221 title "Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis" @default.
• W3138616221 cites W1988035869 @default.
• W3138616221 cites W2015701631 @default.
• W3138616221 cites W2026124542 @default.
• W3138616221 cites W2032062642 @default.
• W3138616221 cites W2037525641 @default.
• W3138616221 cites W2118630839 @default.
• W3138616221 cites W2152208030 @default.
• W3138616221 cites W2158259619 @default.
• W3138616221 cites W2164578214 @default.
• W3138616221 cites W2346851822 @default.
• W3138616221 cites W2419578667 @default.
• W3138616221 cites W2462147264 @default.
• W3138616221 cites W2593200577 @default.
• W3138616221 cites W2752706812 @default.
• W3138616221 cites W2785950685 @default.
• W3138616221 cites W2801731842 @default.
• W3138616221 cites W2888908499 @default.
• W3138616221 cites W2914198163 @default.
• W3138616221 cites W2914739740 @default.
• W3138616221 cites W2920206917 @default.
• W3138616221 cites W2945170445 @default.
• W3138616221 cites W2945880893 @default.
• W3138616221 cites W2972826485 @default.
• W3138616221 cites W2973441550 @default.
• W3138616221 cites W3000262597 @default.
• W3138616221 cites W3015071404 @default.
• W3138616221 cites W3078033824 @default.
• W3138616221 cites W3104928113 @default.
• W3138616221 cites W4249718788 @default.
• W3138616221 cites W978914833 @default.
• W3138616221 doi "https://doi.org/10.1111/1346-8138.15843" @default.
• W3138616221 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33742710" @default.
• W3138616221 hasPublicationYear "2021" @default.
• W3138616221 type Work @default.
• W3138616221 sameAs 3138616221 @default.
• W3138616221 citedByCount "5" @default.
• W3138616221 countsByYear W31386162212022 @default.
• W3138616221 countsByYear W31386162212023 @default.
• W3138616221 crossrefType "journal-article" @default.
• W3138616221 hasAuthorship W3138616221A5002431268 @default.
• W3138616221 hasAuthorship W3138616221A5009716651 @default.
• W3138616221 hasAuthorship W3138616221A5010904358 @default.
• W3138616221 hasAuthorship W3138616221A5043225877 @default.
• W3138616221 hasAuthorship W3138616221A5068749718 @default.
• W3138616221 hasConcept C126322002 @default.
• W3138616221 hasConcept C141105273 @default.
• W3138616221 hasConcept C159654299 @default.
• W3138616221 hasConcept C16005928 @default.
• W3138616221 hasConcept C203014093 @default.
• W3138616221 hasConcept C2776042228 @default.
• W3138616221 hasConcept C2776173921 @default.
• W3138616221 hasConcept C2776266956 @default.
• W3138616221 hasConcept C2777037409 @default.
• W3138616221 hasConcept C2778329239 @default.
• W3138616221 hasConcept C2779824493 @default.
• W3138616221 hasConcept C2780564577 @default.
• W3138616221 hasConcept C2780699399 @default.
• W3138616221 hasConcept C2781431837 @default.
• W3138616221 hasConcept C71924100 @default.
• W3138616221 hasConceptScore W3138616221C126322002 @default.
• W3138616221 hasConceptScore W3138616221C141105273 @default.
• W3138616221 hasConceptScore W3138616221C159654299 @default.
• W3138616221 hasConceptScore W3138616221C16005928 @default.
• W3138616221 hasConceptScore W3138616221C203014093 @default.
• W3138616221 hasConceptScore W3138616221C2776042228 @default.
• W3138616221 hasConceptScore W3138616221C2776173921 @default.
• W3138616221 hasConceptScore W3138616221C2776266956 @default.
• W3138616221 hasConceptScore W3138616221C2777037409 @default.
• W3138616221 hasConceptScore W3138616221C2778329239 @default.
• W3138616221 hasConceptScore W3138616221C2779824493 @default.
• W3138616221 hasConceptScore W3138616221C2780564577 @default.
• W3138616221 hasConceptScore W3138616221C2780699399 @default.
• W3138616221 hasConceptScore W3138616221C2781431837 @default.
• W3138616221 hasConceptScore W3138616221C71924100 @default.
• W3138616221 hasIssue "5" @default.
• W3138616221 hasLocation W31386162211 @default.
• W3138616221 hasOpenAccess W3138616221 @default.
• W3138616221 hasPrimaryLocation W31386162211 @default.
• W3138616221 hasRelatedWork W2022623011 @default.
• W3138616221 hasRelatedWork W3024829390 @default.
• W3138616221 hasRelatedWork W3112462352 @default.
• W3138616221 hasRelatedWork W3138616221 @default.
• W3138616221 hasRelatedWork W4221014321 @default.
• W3138616221 hasRelatedWork W4291151823 @default.
• W3138616221 hasRelatedWork W4361235233 @default.
• W3138616221 hasRelatedWork W4362521478 @default.
• W3138616221 hasRelatedWork W4366822061 @default.
• W3138616221 hasRelatedWork W4210307877 @default.

• next